Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Tirzepatide

Tirzepatide

GIP/GLP-1 · s.c. · Eli Lilly

Data cut 12 November 2026 · page built 16 November 2026 · 7 trial arms · 9 trials with results · 66 registered trials · see on the pipeline board

Summary

Also known as
Zepbound / Mounjaro
Mechanism
GIP/GLP-1
Route
s.c.
Company
Eli Lilly
Highest development stage
approved
Status (as of data cut)
Approved: obesity, T2D, obstructive sleep apnoea (FDA); MACE reduction added to the Mounjaro US label (2026) verify
Next milestone
HFpEF (SUMMIT) and MMO outcomes

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity4 approved / in labelFDA: Zepbound; EMA: Mounjaro (weight management)Zepbound US label (2026)
T2D4 approved / in labelFDA and EMA: MounjaroMounjaro EPAR
CV outcomes4 approved / in labelFDA label (Mounjaro, 2026): MACE reduction in T2D at high CV risk, based on SURPASS-CVOTSURPASS-CVOT
CKD1 phase 2 / signalPhase 2 kidney study and kidney secondary analyses of SURPASS-CVOT; no dedicated phase 3SURPASS-CVOT kidney analysis
HFpEF3 positive phase 3Positive phase 3 (CV death or worsening HF); EU label cites results in section 5.1, not as an indicationSUMMIT
MASH2 phase 3 ongoingPhase 2 positive (SYNERGY-NASH); phase 3 ongoingSYNERGY-NASH (phase 2)
Sleep apnoea4 approved / in labelFDA: Zepbound for moderate-to-severe OSA in adults with obesitySURMOUNT-OSA
Knee OA2 phase 3 ongoingPhase 3 ongoing
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

US prescribing information: indications

Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.

MOUNJARO US label 29.07.2026

1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )

DailyMed

Zepbound US label 28.08.2026

1 INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ( 1 ) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

DailyMed

Mounjaro US label 27.08.2026

1 INDICATIONS AND USAGE MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )

DailyMed

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
EloraTZP phase 2b (obesity + T2D)tirzepatide 15 mgt2d48—−14.8 % vs −3.0 %
Δ −11.8 pp
—−2.4 vs −0.32.9 vs 16.7—————press release
SURMOUNT-1tirzepatide 5 mgobesity722539−16.0 % vs −2.4 %
Δ −13.6 pp
−15.0 % vs −3.1 %
Δ −11.9 pp
—4.3 vs 2.6—24.6 vs 9.58.3 vs 1.76.3 vs 6.8—verified
SURMOUNT-1tirzepatide 10 mgobesity722539−21.4 % vs −2.4 %
Δ −19.0 pp
−19.5 % vs −3.1 %
Δ −16.4 pp
—7.1 vs 2.6—33.3 vs 9.510.7 vs 1.76.9 vs 6.8—verified
SURMOUNT-1tirzepatide 15 mgobesity722539−22.5 % vs −2.4 %
Δ −20.1 pp
−20.9 % vs −3.1 %
Δ −17.8 pp
—6.2 vs 2.6—31.0 vs 9.512.2 vs 1.75.1 vs 6.8—verified
SURMOUNT-2tirzepatide 15 mgt2d72938−15.7 % vs −3.3 %
Δ −12.4 pp
−14.7 % vs −3.2 %
Δ −11.5 pp
−2.1 vs −0.57.4 vs 3.813.8 vs 14.921.9 vs 6.313.2 vs 3.28.7 vs 7.3—verified
SURMOUNT-2tirzepatide 10 mgt2d72938−13.4 % vs −3.3 %
Δ −10.1 pp
−12.8 % vs −3.2 %
Δ −9.6 pp
−2.1 vs −0.53.8 vs 3.89.3 vs 14.920.2 vs 6.310.9 vs 3.25.8 vs 7.3—verified
SURMOUNT-5 (head-to-head)tirzepatide 10/15 mg vs semaglutide 2.4 mg: −13.7 %; treatment discontinuation 21.3 %obesity72751−21.6 %−20.2 %—6.118.443.615.04.8−10.2verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (39)
  • tirzepatide 5 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
    −16.0% (95% CI, −16.8 to −15.2), a weight reduction of 16.1 kg (35.5 lb), with the 5-mg dose
  • tirzepatide 5 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
    −15.0% (95% CI, −15.9 to −14.2) with a 5-mg weekly dose of tirzepatide
  • tirzepatide 5 mg · ae_dc · Results, Participants; Table 4 (27 [4.3])
    Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
  • tirzepatide 5 mg · nausea · Table 4, adverse events in at least 5% of participants
    Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
  • tirzepatide 5 mg · vomiting · Table 4, adverse events in at least 5% of participants
    Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
  • tirzepatide 5 mg · sae · Table 4
    Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
  • tirzepatide 10 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
    −21.4% (95% CI, −22.2 to −20.6), a reduction of 22.2 kg (48.9 lb), with the 10-mg dose
  • tirzepatide 10 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
    −19.5% (95% CI, −20.4 to −18.5) with a 10-mg dose
  • tirzepatide 10 mg · ae_dc · Results, Participants; Table 4 (45 [7.1])
    Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
  • tirzepatide 10 mg · nausea · Table 4, adverse events in at least 5% of participants
    Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
  • tirzepatide 10 mg · vomiting · Table 4, adverse events in at least 5% of participants
    Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
  • tirzepatide 10 mg · sae · Table 4
    Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
  • tirzepatide 15 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Fig. 1B
    −22.5% (95% CI, −23.3 to −21.7), a reduction of 23.6 kg (52.0 lb) with the 15-mg dose
  • tirzepatide 15 mg · weight_tp · Results, Change in Body Weight, paragraph 1; Table 2
    −20.9% (95% CI, −21.8 to −19.9) with a 15-mg dose
  • tirzepatide 15 mg · ae_dc · Results, Participants; Table 4 (39 [6.2])
    Treatment discontinuations due to adverse events were 4.3%, 7.1%, and 6.2% with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 2.6% with placebo.
  • tirzepatide 15 mg · nausea · Table 4, adverse events in at least 5% of participants
    Nausea 155 (24.6) 212 (33.3) 195 (31.0) 61 (9.5)
  • tirzepatide 15 mg · vomiting · Table 4, adverse events in at least 5% of participants
    Vomiting 52 (8.3) 68 (10.7) 77 (12.2) 11 (1.7)
  • tirzepatide 15 mg · sae · Table 4
    Serious adverse events 40 (6.3) 44 (6.9) 32 (5.1) 44 (6.8)
  • tirzepatide 15 mg · nausea · Table 3
    | Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
  • tirzepatide 15 mg · vomiting · Table 3
    | Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
  • tirzepatide 15 mg · disc_any · Figure 1 (trial profile)
    | 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
  • tirzepatide 15 mg · sae · Table 3
    | Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
  • tirzepatide 15 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
    | Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |
  • tirzepatide 15 mg · hba1c · Table 2 + Results
    | Change in HbA₁c, % | -2·07 (0·06) | -2·08 (0·07) | -0·51 (0·07) | ETD -1·55 (-1·74, -1·37); p<0·0001 | ETD -1·57 (-1·76, -1·37); p<0·0001 |
  • tirzepatide 10 mg · nausea · Table 3
    | Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
  • tirzepatide 10 mg · vomiting · Table 3
    | Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
  • tirzepatide 10 mg · disc_any · Figure 1 (trial profile)
    | 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
  • tirzepatide 10 mg · sae · Table 3
    | Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
  • tirzepatide 10 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
    | Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |
  • tirzepatide 10/15 mg · weight_eff · Figure 2A (efficacy estimand, week 72; text-extracted end-po
    −15.4 −21.6
  • tirzepatide 10/15 mg · weight_tp · Results, Change in Body Weight; Table 2
    The least-squares mean percent change in body weight from baseline to week 72 was −20.2% with tirzepatide (95% confidence interval [CI], −21.4 to −19.1)
  • tirzepatide 10/15 mg · ae_dc · Table 3
    Discontinuation of the trial treatment because of adverse events 23 (6.1)
  • tirzepatide 10/15 mg · nausea · Table 3
    Nausea 163 (43.6)
  • tirzepatide 10/15 mg · vomiting · Table 3
    Vomiting 56 (15.0)
  • tirzepatide 10/15 mg · sae · Table 3
    Serious adverse events 18 (4.8)
  • tirzepatide 10/15 mg · sbp · Results, Change in Waist Circumference and Cardiometabolic R
    Systolic blood pressure showed improvements with tirzepatide (least-squares mean change, −10.2 mm Hg; 95% CI, −11.4 to −8.9)
  • tirzepatide 10/15 mg · disc_any · Results, Participants (computed 100−81.6)
    80.2% completed the 72 weeks of trial treatment (81.6% in the tirzepatide group and 78.7% in the semaglutide group)
  • tirzepatide 15 mg · weight_eff · press release
    tirzepatide 15 mg reduced body weight by an average of 34.4 lbs (14.8%
  • tirzepatide 15 mg · ae_dc · press release, safety paragraph
    Treatment discontinuation rates due to adverse events were 10.8% to 27.0% with EloraTZP, 0% to 10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo.

Outcome trials

Cardiovascular and kidney outcome trials

SURPASS-CVOT tirzepatide 5–15 mg vs dulaglutide 1.5 mg (active) · T2D + established ASCVD · n = 13299 · 2025 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE (vs dulaglutide) primary
Composite of death from cardiovascular causes, myocardial infarction, or stroke (95.3% CI reported, adjusted for interim analysis)
0.920.83–1.01801 vs 862verified
Cardiovascular death
Death from cardiovascular causes
0.890.77–1.02367 vs 408verified
All-cause death
Death from any cause
0.840.75–0.94566 vs 669verified
Myocardial infarction
Myocardial infarction (the text does not specify fatal or non-fatal; component of primary composite)
0.860.74–1.00311 vs 357verified
Stroke
Stroke (the text does not specify fatal or non-fatal; component of primary composite)
0.910.76–1.09229 vs 249verified
CV death or worsening HF
Composite of death from cardiovascular causes or hospitalization or urgent visit for heart failure
0.910.81–1.03512 vs 557verified
Expanded MACE (MACE + revasc.)
4-point composite: death from CV causes, myocardial infarction, stroke, or coronary revascularization (secondary end point); comparator dulaglutide 1.5 mg (active control)
0.880.81–0.961089 vs 1217verified
Verbatim quotes (7)
  • 3-point MACE (vs dulaglutide) · Abstract; Results, paragraph 1; Table 2
    A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01
  • Cardiovascular death · Results, paragraph 1; Table 2
    Death from cardiovascular causes occurred in 367 patients (5.6%) in the tirzepatide group and 408 (6.2%) in the dulaglutide group (hazard ratio, 0.89; 95% CI, 0.77 to 1.02).
  • All-cause death · Results, paragraph 1; Table 2
    Death from any cause occurred in 566 patients (8.6%) in the tirzepatide group and 669 (10.2%) in the dulaglutide group (hazard ratio, 0.84; 95% CI, 0.75 to 0.94)
  • Myocardial infarction · Results, paragraph 1; Table 2
    Myocardial infarction occurred in 311 patients (4.7%) and 357 patients (5.4%), respectively (hazard ratio, 0.86; 95% CI, 0.74 to 1.00).
  • Stroke · Results, paragraph 1; Table 2
    Stroke occurred in 229 patients (3.5%) and 249 patients (3.8%), respectively (hazard ratio, 0.91; 95% CI, 0.76 to 1.09).
  • CV death or worsening HF · Results, paragraph 1; Table 2
    Death from cardiovascular causes or hospitalization or urgent visit for heart failure ... occurred in 512 patients (7.8%) in the tirzepatide group and 557 (8.5%) ... (hazard ratio, 0.91; 95% CI, 0.81 to 1.03)
  • Expanded MACE (MACE + revasc.) · Table 2, key secondary end points
    | Death from cardiovascular causes, myocardial infarction, stroke, or coronary revascularization — no. (%) | 1089 (16.5) | 1217 (18.5) | 0.88 (0.81 to 0.96) |

SUMMIT tirzepatide 5–15 mg vs placebo · HFpEF + obesity · n = 731 · 2024 verified

EndpointHR95 % CIEvents, drug vs controlStatus
Cardiovascular death
Adjudicated death from cardiovascular causes (excludes 2 tirzepatide deaths of undetermined cause, which are counted as CV deaths in the composite)
1.580.52–4.838 vs 5verified
All-cause death
Death from any cause
1.250.63–2.4519 vs 15verified
Hospitalisation for heart failure
Adjudicated worsening heart-failure event resulting in hospitalization (first event)
0.440.22–0.8712 vs 26verified
CV death or worsening HF primary
Adjudicated CV death (including undetermined cause) or worsening heart-failure event (hospitalization, IV therapy in urgent care, or intensified oral diuretics)
0.620.41–0.9536 vs 56verified
Verbatim quotes (4)
  • Cardiovascular death · Abstract; Table 2
    adjudicated death from cardiovascular causes occurred in 8 patients (2.2%) and 5 patients (1.4%), respectively (hazard ratio, 1.58; 95% CI, 0.52 to 4.83)
  • All-cause death · Results, Primary End Points; Table 2
    Death from any cause occurred in 19 patients in tirzepatide group and in 15 patients in the placebo group (hazard ratio, 1.25; 95% CI, 0.63 to 2.45)
  • Hospitalisation for heart failure · Table 2
    Adjudicated worsening heart-failure event resulting in hospitalization — no. (%) 12 (3.3) 1.8 26 (7.1) 3.9 0.44 (0.22 to 0.87)
  • CV death or worsening HF · Results, Primary End Points; Table 2; Figure 1
    occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (...hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)

Other indications

SUMMIT Tirzepatide · HFpEF + obesity · 104 weeks · n = 731 seed

CV death or worsening HF HR 0.62; KCCQ-CSS +6.9 points

MeasureDrugControlDifference (95 % CI)Status
Cardiovascular death or worsening heart-failure event (time to first event)
week 104
+9.9+15.3+0.6 (+0.4 to +0.9) hazard ratioverified
KCCQ clinical summary score, change from baseline
week 52
+19.5+12.7+6.9 (+3.3 to +10.6) points (0-100)verified
Verbatim quotes (2)
  • Cardiovascular death or worsening heart-failure event (time to first event)
    Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)
  • KCCQ clinical summary score, change from baseline
    the mean (±SD) change in the KCCQ-CSS was 19.5±1.2 in the tirzepatide group as compared with 12.7±1.3 in the placebo group (between-group difference, 6.9; 95% CI, 3.3 to 10.6; P<0.001)

SURMOUNT-OSA Tirzepatide · Obstructive sleep apnoea + obesity · 52 weeks · n = 469 seed

AHI −25.3 vs −5.3 events/h (trial 1), −29.3 vs −5.5 (trial 2, on PAP); FDA label Dec 2024

MeasureDrugControlDifference (95 % CI)Status
Apnea-hypopnea index, change from baseline trial 1
week 52
−25.3−5.3−20.0 (−25.8 to −14.2) events/hverified
Apnea-hypopnea index, change from baseline trial 2
week 52
−29.3−5.5−23.8 (−29.6 to −17.9) events/hverified
Verbatim quotes (2)
  • Apnea-hypopnea index, change from baseline
    In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2)
  • Apnea-hypopnea index, change from baseline
    In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9)

SYNERGY-NASH Tirzepatide · MASH F2–F3 · 52 weeks · n = 190 seed

MASH resolution without worsening fibrosis 44–62 % vs 10 %

MeasureDrugControlDifference (95 % CI)Status
MASH resolution without worsening of fibrosis - tirzepatide 10 mg 10 mg
week 52
+56.0+10.0+46.0 (+29.0 to +62.0) percentage pointsverified
MASH resolution without worsening of fibrosis - tirzepatide 15 mg 15 mg
week 52
+62.0+10.0+53.0 (+37.0 to +69.0) percentage pointsverified
MASH resolution without worsening of fibrosis - tirzepatide 5 mg 5 mg
week 52
+44.0+10.0+34.0 (+17.0 to +50.0) percentage pointsverified
Verbatim quotes (3)
  • MASH resolution without worsening of fibrosis - tirzepatide 10 mg
    56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62)
  • MASH resolution without worsening of fibrosis - tirzepatide 15 mg
    62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69)
  • MASH resolution without worsening of fibrosis - tirzepatide 5 mg
    44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50)

Ongoing outcome trials

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
SURMOUNT-MMOTirzepatideObesity, morbidity and mortality
Obesity without diabetes (T2D excluded), established CVD or risk factors
Composite of death and CV events15374active not recruiting2027-10NCT05556512

Registered trials (66)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07265752
Tirzepatide for the Treatment of Cannabis Use Disorder
AddictionPhase 2not yet recruiting2027-03 → 2028-066not yet recruitingNCT07265752
TirBaS
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
ObesityPhase 3not yet recruiting2027-01 → 2028-1270not yet recruitingNCT07829198
CUD
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
AddictionPhase 2not yet recruiting2026-11 → 2028-03100not yet recruitingNCT07468552
T-STEM
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
AddictionPhase 2recruiting2026-10 → 2031-07228recruitingNCT07825857
TIRZE-PAP
Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea
Sleep apnoeaPhase 3not yet recruiting2026-10 → 2028-12256not yet recruitingNCT07846865
NCT07906041
Tirzepatide and Organ-specific Biological Aging
OtherPhase 2enrolling by invitation2026-10 → 2028-0422enrolling by invitationNCT07906041
TOPAZ
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
NeurologyPhase 3recruiting2026-09 → 2028-05726recruitingNCT07734792
NCT07734870
Tirzepatide for Treatment of CCCA
OtherPhase 2recruiting2026-09 → 2028-0520recruitingNCT07734870
ADVANCE-SURMOUNT-KIDS
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
ObesityPhase 3recruiting2026-09 → 2029-12150recruitingNCT07817875
EXER-MED
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
ObesityPhase 3not yet recruiting2026-08 → 2026-1224not yet recruitingNCT07298915
NCT07671248
Tirzepatide in the Treatment of Cannabis Use Disorder
AddictionPhase 3not yet recruiting2026-08 → 2028-0715not yet recruitingNCT07671248
CLARA
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
OtherPhase 2not yet recruiting2026-08 → 2028-03168not yet recruitingNCT07676331
TRI-MR
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder
AddictionPhase 2active not recruiting2026-08 → 2030-0245active not recruitingNCT07693608
NCT07573163
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
OtherPhase 2recruiting2026-07 → 2028-0734recruitingNCT07573163
DUAL-HFrEF
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
HFpEFPhase 3not yet recruiting2026-07 → 2027-0660not yet recruitingNCT07738276
NCT07046819
Tirzepatide in MetALD
OtherPhase 2recruiting2026-06 → 2027-07120recruitingNCT07046819
NCT07602699
Multi-Site Trial of Tirzepatide for Smoking Cessation
AddictionPhase 2recruiting2026-06 → 2028-03300recruitingNCT07602699
TREAT-EC
Tirzepatide in the Treatment of Endometrial Cancer
OtherPhase 2not yet recruiting2026-06 → 2028-0130not yet recruitingNCT07605247
NCT07527910
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
MASHPhase 2recruiting2026-05 → 2030-03204recruitingNCT07527910
NCT07220473
Tirzepatide to Slow Biological Aging
OtherPhase 2recruiting2026-02 → 2027-1190recruitingNCT07220473
SURMOUNT-1
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
ObesityPhase 3recruiting2026-02 → 2027-022539recruitingNCT07481747
TAB
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
AddictionPhase 2recruiting2026-01 → 2027-09310recruitingNCT06651177
OOB
Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)
Alzheimer'sPhase 2not yet recruiting2026-01 → 2027-0546not yet recruitingNCT07292519
NCT07834398
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
ObesityPhase 3completed2025-11 → 2026-04150Completed; results not in the atlas yetNCT07834398
NCT06994338
Tirzepatide for Alcohol Use Disorder
AddictionPhase 2recruiting2025-10 → 2026-0842recruitingNCT06994338
LOCITT
The Long COVID Treatment Trial
OtherPhase 2active not recruiting2025-10 → 2026-121000active not recruitingNCT07128082
STREAM
Study of Tirzepatide for Recovery and Alcohol Use Management
AddictionPhase 2recruiting2025-09 → 2027-0320recruitingNCT06727331
LIBERATE
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
AddictionPhase 2recruiting2025-09 → 2027-12105recruitingNCT06847399
TILT-2024
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
OtherPhase 2recruiting2025-09 → 2029-0932recruitingNCT07091734
COMMIT-UC
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
ObesityPhase 3recruiting2025-06 → 2028-04350recruitingNCT06937086
COMMIT-CD
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
ObesityPhase 3recruiting2025-06 → 2028-05290recruitingNCT06937099
DUALPSYCHIATRY
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
AddictionPhase 2recruiting2025-05 → 2028-08108recruitingNCT06939088
NCT06976853
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
OtherPhase 2recruiting2025-05 → 2028-0560recruitingNCT06976853
NCT06745128
Tirzepatide for Obesity and Meth Use Disorder
AddictionPhase 2completed2025-02 → 2026-0235Completed; results not in the atlas yetNCT06745128
NCT06918405
Efficacy and Safety of Tirzepatide for Weight Management
ObesityPhase 3active not recruiting2025-01 → 2026-06440active not recruitingNCT06918405
NCT06246799
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
T2DPhase 3recruiting2024-11 → 2029-04256recruitingNCT06246799
GRABS-0
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
ObesityPhase 3active not recruiting2024-10 → 2026-1030active not recruitingNCT06162715
TOGETHER-PsO
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ObesityPhase 3completed2024-09 → 2026-01281Completed; results not in the atlas yetNCT06588283
TOGETHER-PsA
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ObesityPhase 3completed2024-09 → 2025-11279Completed; results not in the atlas yetNCT06588296
SURMOUNT-ADOLESCENTS-2
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
ObesityPhase 3recruiting2024-06 → 2027-10300recruitingNCT06439277
NCT05659368
Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1
OtherPhase 2unknown2024-01 → 2024-1010unknownNCT05659368
SURMOUNT-ADOLESCENTS
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
ObesityPhase 3active not recruiting2023-10 → 2026-06160active not recruitingNCT06075667
SURMOUNT-MAINTAIN
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
ObesityPhase 3completed2023-09 → 2026-01441Completed; results not in the atlas yetNCT06047548
SURPASS-CN-MONO
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
T2DPhase 3completed2023-08 → 2024-10206Completed; results not in the atlas yetNCT05963022
TREASURE-CKD
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
CKDPhase 2completed2023-02 → 2026-07134Completed; results not in the atlas yetNCT05536804
SURPASS-CN-INS
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
T2DPhase 3completed2023-02 → 2024-07257Completed; results not in the atlas yetNCT05691712
SURMOUNT-MMO
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
CV outcomesPhase 3active not recruiting2022-10 → 2027-1015374NCT05556512
SURMOUNT-OSA
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
Sleep apnoeaPhase 3completed2022-06 → 2024-03469AHI −25.3 vs −5.3 events/hNCT05412004
SURPASS-PEDS
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
T2DPhase 3completed2022-04 → 2024-0799Completed; results not in the atlas yetNCT05260021
SURMOUNT-CN
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
ObesityPhase 3completed2021-09 → 2022-12210Completed; results not in the atlas yetNCT05024032
SURMOUNT-J
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
ObesityPhase 3completed2021-05 → 2023-06267Completed; results not in the atlas yetNCT04844918
SUMMIT
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
HFpEFPhase 3completed2021-04 → 2024-07731CV death or worsening HF HR 0.62 (0.41–0.95)NCT04847557
SURMOUNT-2
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
ObesityPhase 3completed2021-03 → 2023-03938Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT04657003
SURMOUNT-3
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
ObesityPhase 3completed2021-03 → 2023-04579Completed; results not in the atlas yetNCT04657016
SURMOUNT-4
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
ObesityPhase 3completed2021-03 → 2023-04783Completed; results not in the atlas yetNCT04660643
SURPASS-6
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
T2DPhase 3completed2020-10 → 2022-101428Completed; results not in the atlas yetNCT04537923
SURPASS-CVOT
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
CV outcomesPhase 3completed2020-05 → 2025-0613299MACE HR 0.92 (0.83–1.01) vs dulaglutide: non-inferiorNCT04255433
SURPASS-AP-Combo
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
T2DPhase 3completed2019-12 → 2021-11917Completed; results not in the atlas yetNCT04093752
SURMOUNT-1
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
ObesityPhase 3completed2019-12 → 2022-042539Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT04184622
SYNERGY-NASH
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
MASHPhase 2completed2019-11 → 2023-12190MASH resolution 44–62 % vs 10 % (phase 2)NCT04166773
SURPASS-5
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
T2DPhase 3completed2019-08 → 2020-12475Completed; results not in the atlas yetNCT04039503
SURPASS-1
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
T2DPhase 3completed2019-06 → 2020-10478Completed; results not in the atlas yetNCT03954834
SURPASS J-mono
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
T2DPhase 3completed2019-05 → 2021-03636Completed; results not in the atlas yetNCT03861052
SURPASS-3
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
T2DPhase 3completed2019-04 → 2020-121444Completed; results not in the atlas yetNCT03882970
SURPASS J-combo
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
T2DPhase 3completed2019-03 → 2021-01443Completed; results not in the atlas yetNCT03861039
SURPASS-4
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
T2DPhase 3completed2018-11 → 2021-012002Completed; results not in the atlas yetNCT03730662

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Tirzepatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/tirzepatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.